

REMARKS

Favorable reconsideration is respectfully requested in view of the foregoing amendments and the following remarks.

Applicants sincerely thank the Examiner for discussing this application with Applicants' representative over the telephone on October 1, 2007. During the discussion, the Examiner indicated that claim 14 should be in condition for allowance if "pharmaceutical composition" is amended to recite "composition."

I. CLAIM STATUS AND AMENDMENTS

Claims 1, 14 and 43 were pending in this application when last examined.

Claims 1 and 43 were indicated as allowed.

Claim 14 was examined on the merits and rejected.

Claim 14 is amended to recite "composition" instead of "pharmaceutical composition."

No new matter has been added.

II SPECIFICATION AND DRAWINGS

On pages 2-3 of the Office Action, the drawings and specification were objected to by the Examiner for failure to recite sequence identifiers. In particular, Figures 1-2, 5 and 7-8 were objected to for reciting sequences and not sequence identifiers. Further, the brief description of the drawings, on pages 5-8 of the specification, were objected to for not disclosing SEQ ID NOS.

The brief description of the drawings is amended to recite SEQ ID NOS for all sequences recited in Figures 1-2, 5 and 7-8.

Furthermore, there is submitted herewith a paper copy of a revised substitute Sequence Listing, together with a disk containing a computer readable version of the revised substitute Sequence Listing. The paper and computer readable versions of the revised substitute Sequence

Listing are identical. The revised substitute Sequence Listing has been run through the PTO Checker software (version 4.4.0) and no errors were found.

The revised substitute Sequence Listing recites sequences for SLC21A12 and OATPRP4 proteins, as required in the Office Action.

No new matter has been added by these amendments.

It is therefore respectfully submitted that the Examiner's objections to the specification, drawings and Sequence Listing should be withdrawn. It is also respectfully submitted that the application is now in compliance with the Sequence Rules under 37 CFR 1.821-1.825.

III. ENABLEMENT REJECTION

On page 4 of the Office Action, claim 14 remained rejected under 35 U.S.C. § 112, first paragraph, as lacking enablement for the term "pharmaceutical composition."

Claim 14 is amended to recite "composition" instead of "pharmaceutical composition." Such an amendment was indicated as placing this claim in condition for allowance during the above-noted telephone conversation between the Examiner and Applicants' representative. Applicants therefore suggest that this rejection is overcome as applied to amended claim 14.

Attorney Docket No. 2007_0367A
Serial No. 10/506,308
October 5, 2007

CONCLUSION

In view of the foregoing amendments and remarks, the present application is in condition for allowance and an early notice to that effect is hereby requested.

If the Examiner has any comments or proposals for expediting prosecution, please contact the undersigned attorney at the telephone number below.

Respectfully submitted,

Atsushi NAKANISHI et al.

By: Walche
Warren M. Cheek
Registration No. 33,367
Attorney for Applicants

WMC/WRS/led
Washington, D.C. 20006-1021
Telephone (202) 721-8200
Facsimile (202) 721-8250
October 5, 2007